| HOME >> BIOLOGY >> TECHNOLOGY |
BETHESDA, Md., Dec. 20, 2010 /PRNewswire/ -- Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope. Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress.
"Uterine fibroids are the leading cause of women's surgeries worldwide," says Russ DeLonzor, President and Chief Operating Officer of Halt. "Currently women must choose between suffering with their symptoms or sacrificing their uterus." The symptoms can be severe, ranging from acute pelvic pain, urinary incontinence, and painful intercourse, to excessive menstrual bleeding.
"Hysterectomy surgeries can be highly traumatic for women," says DeLonzor. "It's not only an emotional decision, but also a painful one, with a typical six-week recovery time. Halt Medical was formed with a single goal in mind," adds DeLonzor, "to give women suffering with the awful symptoms caused by fibroids an alternative to losing their uterus."
The Halt Fibroid System is a precise, minimally invasive outpatient procedure that allows women to return to normal activities in just 3 – 4 days. A slender probe is inserted into the fibroid under ultrasound guidance. Once in position, the system delivers a specified amount of energy to the fibroid. The heat generated in the process destroys the fibroid, relieving the symptoms while sparing the uterus.
"We commend the NIH for sponsoring this forum," DeLonzor says. "Uterine fibroids are a significant public health issue, and we are honored to share the results of our Latin American Studies."
The results of Halt's international studies have led to recent approvals for treating uterine fibroids in Canad
'/>"/>
| SOURCE Halt Medical, Inc. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
3. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
4. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
5. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
6. BioMS Medical Announces Second Quarter 2008 Results
7. ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference
8. Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation
9. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
10. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
11. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |